Nathanael Gray
Krishnan-Shah Family Professor, Chemical and Systems Biology
Nathanael Gray, Co-Lead for Medicinal Chemistry, is a transformative individual for the IMA. As a leading medicinal chemist in academia developing anti-cancer small molecule inhibitors, he pioneered the development of protein degradation as a means of targeting undruggable proteins for inhibition. He has forged strong collaborations with venture capitalist firms and industry, holds numerous patents, and has received significant funding from the NIH.
Prior to joining Stanford's faculty, he was a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana Farber Cancer Institute. Previously, Nathanael was the Director of Biological Chemistry at the Novartis Institute for Genomics (GNF) in San Diego where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs including ceritinib, siponimod and ABL001. Dr. Gray received his PhD in organic chemistry from Professor Peter Schultz at the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995.